Contacts :

Alexion Pharmaceuticals, Inc.
Irving Adler
Executive Director,
Corporate Communications
(203) 271-8210

Alexion Pharmaceuticals, Inc.
Kim Diamond (Media) Senior Director,
Corporate Communications
(203) 439-9600
 Rx Communications (Investors)
 Rhonda Chiger
 (917) 322-2569

Alexion Reports Fourth Quarter and Full Year 2013 Results and Provides Financial Guidance for 2014

- Soliris® (eculizumab) Net Product Sales Increased 37 Percent
to $1.551 Billion in 2013 -

- 2013 Non-GAAP EPS Increased 47 Percent to $3.08; GAAP EPS of $1.27 -

- Steady Soliris Growth in PNH Worldwide -

- aHUS Launch Progresses in U.S. and Europe; Japan Launch Commences in Q4 -

- Strong Progress Across Lead Development Programs -
- Establishment of mRNA Research Capabilities Through Strategic Agreement With Moderna Theraputics -

- 2014 Guidance: Revenue $2.00 to $2.02 Billion; Non-GAAP EPS $3.70 to $3.80 -

Full Year 2013 Financial Highlights

2013 net product sales increased 37 percent to $1.551 billion, compared to $1.134 billion in 2012.

2013 GAAP net income was $252.9 million, or $1.27 per share, which was impacted by $0.48 per share related to a non-cash tax expense associated with centralizing certain business operations and $0.17 per share related to impairment of intangible assets. 2012 GAAP net income was $254.8 million, or $1.28 per share.

2013 non-GAAP net income increased 47 percent to $624.2 million, or $3.08 per share, compared to 2012 non-GAAP net income of $425.2 million, or $2.13 per share.

Fourth Quarter 2013 Financial Highlights

Q4 2013 net product sales increased 38 percent to $441.9 million, compared to $320.5 million in Q4 2012.


The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, January 30, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Alexion Pharmaceuticals, Inc..


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019) Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019) Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account